Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- Technology Transfer Being Stimulated in Japan: Monkasho Symposium
April 8, 2002
- CORPORATE ROUNDUP NEWS IN BRIEF
April 8, 2002
- Sawai Sees 23.48% Reduction in NHI Prices
April 1, 2002
- Only 10-20% of Patients with Osteoporosis Receiving Treatment: WLJ Seminar
April 1, 2002
- Taiyo to Start Strategy to Promote Use of Generics
April 1, 2002
- JACCRO Established to Promote Clinical Trials for Cancer
April 1, 2002
- BUSINESS NEWS IN BRIEF
April 1, 2002
- RenaScience Offers Renal Disease-Related Genes to Companies
April 1, 2002
- Pele Appointed as Japan's Educational Ambassador for ED: Pfizer
April 1, 2002
- Utilization of Medicinal Plants Reported by Korosho
April 1, 2002
- Our Growth Not Enough for Survival: Mr Yokotsuka of Sumitomo
April 1, 2002
- PMS Measures to Be Strengthened in PAL Amendment
April 1, 2002
- Kansai Bio Conference in Kobe Focuses on Regenerative Medicine
April 1, 2002
- DIAGNOSTIC NEWS IN BRIEF
April 1, 2002
- Ono's Elaspol Recommended for Approval by CDFS Department
April 1, 2002
- Makers Are Not Supplying Sufficient Information to Pharmacies: Survey
April 1, 2002
- Meiji Licenses Carbapenem from Wyeth Lederle
April 1, 2002
- Korosho to List All Generics on Website
April 1, 2002
- AJD Develops New Medical Bill Processing System
April 1, 2002
- Suntory, Daiichi to Codevelop Memantine for Alzheimer's Dementia
April 1, 2002
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…